Outro

On this episode of Stock Movers:
- Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO.
- Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter..
- M&S expects profit in the second half to rebound to at least last year’s level as the British retailer tries to move on from a costly cyberattack.

See omnystudio.com/listener for privacy information.